Evaluation of the Effect for National Centralized Drug Procurement Policy of PPIs in 33 Hospitals in Wuhan
10.13748/j.cnki.issn1007-7693.20230019
- VernacularTitle:武汉33家医院执行质子泵抑制剂集采政策的效果评估
- Author:
Zhijuan LIN
1
;
Li LIU
1
;
Wenjuan HE
1
;
Zhiliang ZHANG
1
;
Zhaohui GUO
1
;
Ping LIU
1
;
Quan LEI
1
;
Ying XU
1
Author Information
1. Department of Pharmacy, Wuhan Fourth Hospital, Wuhan 430033, China
- Publication Type:Journal Article
- Keywords:
national centralized drug procurement；proton pump inhibitors；utilization rate
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(12):1723-1728
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To analyze the use status and development trend of proton pump inhibitors(PPIs) in 33 hospitals in Wuhan, Hubei Province after the implementation of the national centralized drug procurement(NCDP) policy, and to provide reference for promoting the subsequent rational use of NCDP drugs and improving related policies.
METHODS
To make statistics and analysis of purchasing amount of PPIs, defined daily dose system(DDDs), defined daily dose consumption(DDDc) and utilization rate of 33 hospitals in Wuhan in 2019 and 2022.
RESULTS
After the implementation of the NCDP policy, the total purchasing amount of PPIs decreased by 53.6%, DDDs decreased by 15.4%, DDDc decreased by 45.2%, and the utilization rate of PPIs injectable dosage forms decreased by 12.6%. After NCDP, the highest growth rate of oral dosage forms was omeprazole(5.7%), followed by rabeprazole(5.0%), while injectable dosage forms showed a significant difference in utilization rate, with a significant decline in NCDP varieties and a significant increase in non-NCDP varieties. The overall NCDP utilization rate of PPIs in Wuhan was 64.9%, with little difference among hospitals of different grades.
CONCLUSION
The NCDP policy achieves the purpose of reducing the drug cost of patients and improving the accessibility of drugs, and is more optimized in the selection of dosage forms, which is in line with the policy expectations overall; but the quantity and price of PPIs in Wuhan decreased after NCDP, and highlighted a certain tendency in the selection of varieties. In the future, we still need to optimize measures to guide clinical priority in the selection of NCDP drugs, to ensure and improve the implementation of NCDP policy.
